IL17A and chronic obstructive pulmonary disease: The VGVAPG peptide did not affect IFN-γ and IL-17A expression in CD4+ T-cells from COPD patients (Fig. 4b, c) and did not modify cytokine expression in CD8+ T-cells from either controls or COPD patients (data not shown).